Last reviewed 2026-04-19 · How we verify

intravenous14C-ODM-201

Orion Corporation, Orion Pharma · Phase 1 active Small molecule

intravenous14C-ODM-201 is a Small molecule drug developed by Orion Corporation, Orion Pharma. It is currently in Phase 1 development.

At a glance

Generic name	intravenous14C-ODM-201
Sponsor	Orion Corporation, Orion Pharma
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Mass Balance, Pharmacokinetics, Biotransformation and Bioavailability Study of ODM-201 in Healthy Male Subjects (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

intravenous14C-ODM-201 CI brief — competitive landscape report
intravenous14C-ODM-201 updates RSS · CI watch RSS
Orion Corporation, Orion Pharma portfolio CI

Frequently asked questions about intravenous14C-ODM-201

What is intravenous14C-ODM-201?

intravenous14C-ODM-201 is a Small molecule drug developed by Orion Corporation, Orion Pharma.

Who makes intravenous14C-ODM-201?

intravenous14C-ODM-201 is developed by Orion Corporation, Orion Pharma (see full Orion Corporation, Orion Pharma pipeline at /company/orion-corporation-orion-pharma).

What development phase is intravenous14C-ODM-201 in?

intravenous14C-ODM-201 is in Phase 1.

Manufacturer: Orion Corporation, Orion Pharma — full pipeline
Compare: intravenous14C-ODM-201 vs similar drugs
Pricing: intravenous14C-ODM-201 cost, discount & access